BioCryst Pharmaceuticals Inc. has announced that it will present nine abstracts from its hereditary angioedema $(HAE)$ portfolio at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, scheduled for February 27 to March 2, 2026, in Philadelphia. The presentations will include six abstracts with new clinical trial and real-world outcomes for ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for HAE patients aged 2 and older. Three additional abstracts will feature new clinical trial data on navenibart, a long-acting monoclonal antibody plasma kallikrein inhibitor in development for HAE prophylaxis. Among these, a late-breaking abstract will present interim results from the ALPHA-SOLAR trial, demonstrating long-term, sustained HAE attack suppression with navenibart administered every 3 or 6 months. The results are scheduled to be presented at the upcoming AAAAI meeting and are available as abstracts in an online supplement to The Journal of Allergy and Clinical Immunology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652617-en) on February 11, 2026, and is solely responsible for the information contained therein.